Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating activities:
Net loss	$ (30,219)	$ (25,939)
Items not involving cash:
Depreciation	283	445
Amortization of discount on term loan	388	156
Deferred income tax recovery	(73)	(94)
Stock-based compensation	1,567	2,050
Unrealized foreign exchange (gain) loss	(161)	269
Gain on termination of collaboration agreement (note 9c)		(4,398)
Changes in operating assets and liabilities:
Accounts receivable	(54)	349
Prepaid expenses and other current assets	208	(1,239)
Accounts payable and accrued expenses	3,694	919
Net cash used in operating activities	(24,367)	(27,482)
Investing activities:
Purchases of property, plant and equipment	(645)	(337)
Purchases of marketable securities	(76,064)	(50,130)
Proceeds from marketable securities	70,684	34,036
Net cash used in investing activities	(6,025)	(16,431)
Financing activities:
Proceeds from issuance of second tranche under term loan, net of issuance costs		8,453
Issuance of common shares, net of issuance costs (note 9a)		102,842
Issuance of common shares pursuant to exercise of stock options	87	262
Net cash provided by financing activities	87	111,557
Effect of exchange rate changes on cash and cash equivalents	222	(168)
Increase (decrease) in cash and cash equivalents	(30,083)	67,476
Cash and cash equivalents, beginning of period	67,754	20,486
Cash and cash equivalents, end of period	37,671	87,962
Supplemental disclosures:
Interest paid	702	338
Interest received	1,938	518
Cash paid for operating lease	469	465
Supplemental disclosures of non-cash transactions:
Fair value of stock options exercised on a cashless basis	$ 354	1,112
Issuance of preferred shares in exchange for common shares (note 9b)		21,825
Conversion of preferred shares to common shares (note 9b)		9,893
Teva Pharmaceuticals International GmbH and Teva Canada Limited [Member]
Supplemental disclosures of non-cash transactions:
Termination of Teva agreement through cancellation of common shares (note 9c)		$ 4,470